Duan Yongping
H&H International Investment
Duan Yongping Biogen Inc stake
total: 40
H&H International Investment BIIB trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2020 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2020 Q2
According to 2026 Q2 report, Duan Yongping doesn't hold any Biogen Inc (BIIB) shares. To date, the estimated cost basis is nearly $316.4 for "buy" trades and estimated average "sell" price is $316.4. H&H International Investment first purchased BIIB in 2020 Q1, initially acquiring 10,000 shares. Since the initial investment in Biogen Inc (BIIB), H&H International Investment has made 1 more transaction.
When did Duan Yongping sell Biogen Inc (BIIB)?
Duan Yongping sold off the entire Biogen Inc (BIIB) position in 2020 Q2.
When did Duan Yongping buy Biogen Inc (BIIB)?
Duan Yongping first invested in Biogen Inc (BIIB) in 2020 Q1 at the reported quarter-end price of $316.40 per share.
What's the cost basis of H&H International Investment's BIIB stake?
The estimated cost basis for Biogen Inc (BIIB) stake is around $316.40 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $316.40
- Weighted AVG sell price:
- $316.40
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.